Diagn Microbiol Infect Dis . Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study

[tetano]

Diagn Microbiol Infect Dis


. 2021 Sep 9;101(4):115537.
doi: 10.1016/j.diagmicrobio.2021.115537. Online ahead of print.
Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study


Huanyuan Luo ¹ , Dorothée Camilleri ² , Ibon Garitaonandia ³ , Dilshat Djumanov ² , Tao Chen ¹ , Ulrike Lorch ² , Jörg Täubel ⁴ , Duolao Wang ⁵



Affiliations

• PMID: 34619569
• DOI: 10.1016/j.diagmicrobio.2021.115537

Abstract

We aim to study kinetics of anti-SARS-CoV-2 IgG antibody levels in subjects with COVID-19 for up to 11 months and the potential influential factors. The study was a prospective longitudinal study. The analyses were based on 77 serum/plasma samples with a mean of 4 samples per participant (range 1 - 18) in 20 participants with at least one positive Polymerase Chain Reaction testing result from 19 March 2020 up to 10 February 2021. Among the subjects (median age 34.5 years, 65% male), IgG level declined with the follow-up time (per month; geometric mean ratio [GMR] 0.73; 95% CI, 0.72 - 0.74). In a small sample of subjects from the general population with COVID-19, IgG levels declined non-linearly from month 2 to 11 with individual heterogeneity in quantity and changing speed and may be associated with gender, race and the loss of smell and taste.

Keywords: COVID-19; IgG; SARS-CoV-2; antibody; coronavirus; kinetics.